Steven Limentani

Steven Limentani

Atrium Health - / United States
Others
AD Scientific Index ID: 4928383
person_outline Steven Limentani's MOST POPULAR ARTICLES
1-) A phase 2 study of bortezomib in relapsed, refractory myelomaPG Richardson, B Barlogie, J Berenson, S Singhal, S Jagannath, D Irwin, ...New England Journal of Medicine 348 (26), 2609-2617, 200333242003
2-) A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaS Jagannath, B Barlogie, J Berenson, D Siegel, D Irwin, PG Richardson, ...British journal of haematology 127 (2), 165-172, 20049552004
3-) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)–positive breast cancer after prior HER2 …HA Burris, HS Rugo, SJ Vukelja, CL Vogel, RA Borson, S Limentani, ...Journal of Clinical Oncology 29 (4), 398-405, 20117552011
4-) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomibPG Richardson, H Briemberg, S Jagannath, PY Wen, B Barlogie, ...Journal of clinical oncology 24 (19), 3113-3120, 20067952006
5-) First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE …HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ...The Lancet Oncology 18 (9), 1159-1171, 20173942017